RFID Traceability for Healthcare
  • FR
  • EN
  • Access
  • Careers
  • Contact us

Biolog-id has announced that it is marketing its universal RFID smart storage kit for blood supply management, a world first for Switzerland

27/06/2017 - As part of its international development strategy, Biolog-id – a leader and pioneer in global management solutions for sensitive health products – has announced that it is marketing its first universal RFID (Radio Frequency Identification) storage kit for blood bags at the Hôpital du Jura bernois, located at the Moutier and Saint-Imier sites.

Smart Storage: a universal kit that fits all medical refrigerators

The Biolog solution is based on three elements. Firstly, RFID labels – featuring memory chips that contain important information about the patient and the product itself – are affixed to the blood bags. The second element is a series of equipment, with the flagship product being a universal RFID storage kit called Smart Storage (SST). Suitable for all medical refrigerators on the market, the SST kit not only allows the storage of blood products, but also provides real-time information on their precise location, status, stock levels and log data (including temperature). Finally, the software – the final element in the solution – processes the data stored in and exchanged with the chip.

"This means that the Transfusion Centre can access real-time information on stock levels and the status of each blood bag in far-off hospital departments," explains the Director of Healthcare at the Hôpital du Jura bernois, Cédric Mafille. "With this system, unused blood bags can be returned to storage thanks to proof that they have been kept in the conditions required by regulations, and can be assigned to patients who require them. Until now, we were billed by the La Chaux-de-Fonds Centre for all blood product returns. By implementing SST, transfusions have become safer and we stand to make significant savings. In addition, by removing the need for our laboratory technicians to enter traceability information, this medical system means we can optimise their working time and prevent any potential transcription errors. The benefits of blood bank decentralisation are now clear, and our calculations show that this investment will have paid for itself in two years."


About the Hôpital du Jura bernois

The Saint-Imier and Moutier hospitals merged in 2000 to the Hôpital du Jura bernois SA. This new structure improves networking and sharing of skills between specialists from both institutions. The Hôpital du Jura bernois employs 760 people and admits over 5,000 inpatients every year. Over the same period, 15,000 patients are treated in the accident and emergency department.

The mission of care entrusted to the Hôpital du Jura bernois covers basic medicine in the fields of general medicine, visceral and orthopaedic surgery, gynaecology and obstetrics, geriatric medicine and emergency rescue (pre-hospital treatment). Specialised services are also offered on an outpatient basis.

The Hôpital du Jura bernois features extremely high-quality technical facilities and the latest equipment, particularly in the field of medical imaging. An accident and emergency department and an operating block, open 24 hours a day at each site, provide round-the-clock access to healthcare in the areas served by the Hôpital du Jura bernois.


About Biolog-id

Founded in 2005, Biolog-id is the company behind a disruptive technological solution that fundamentally alters the way that both the transfusion chain and chemotherapy treatment are managed. This technological breakthrough – a major creator of value – is a valuable contributor to the digital modernisation of health and makes Biolog-id an essential player in the concept of blood supply management.

The company's in-depth expertise in RFID traceability makes it the leading global player in the field of smart solutions for sensitive health products.

After many years of R&D efforts followed by a long process of approving the solutions developed in partnership with its first clients (the LFB Group, the French blood transfusion service Etablissement Français du Sang, and the Institut Curie) and with the regulating authorities, Biolog-id is now experiencing growth and predicts that over the next five years, it will see an average annual increase in turnover of 30-50%.

In 2016, the company reported turnover of €7m, marking the beginning of its penetration into its target markets. In 2017, after opening two subsidiaries in Spain and Italy, Biolog-id is preparing to begin operating in the United States.

The company's headquarters are located in Paris, and it has a manufacturing site in Bernay (Eure). It has 40 employees and plans to recruit around 10 staff members per year in France and abroad to support its growth.


Biolog-id is supported by Xerys Gestion, a specialist investment capital portfolio management company that is regulated by the French Financial Markets Authority.

Biolog-id contact: Brigitte Postel.
Tel.: +33 (0)6 10 71 25 10.